CI
CRSP icon

Capital International’s CRISPR Therapeutics CRSP Stock Holding History

Capital International’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Hold
56,066
– – 0.1% 133
2026
Q1 		$2.67M Buy
56,066
+547
+1% +$28.9K 0.1% 132
2025
Q4 		$2.91M Sell
55,519
-6,033
-10% -$361K 0.1% 131
2025
Q3 		$3.99M Hold
61,552
– – 0.14% 122
2025
Q2 		$2.99M Sell
61,552
-10,511
-15% -$407K 0.11% 126
2025
Q1 		$2.45M Sell
72,063
-56,317
-44% -$2.39M 0.11% 127
2024
Q4 		$5.05M Buy
128,380
+2,776
+2% +$131K 0.21% 104
2024
Q3 		$5.9M Sell
125,604
-527
-0.4% -$26.7K 0.25% 95
2024
Q2 		$6.81M Sell
126,131
-639
-0.5% -$37K 0.31% 81
2024
Q1 		$8.64M Buy
126,770
+31,908
+34% +$2.28M 0.41% 74
2023
Q4 		$5.94M Sell
94,862
-108
-0.1% -$5.97K 0.3% 89
2023
Q3 		$4.31M Sell
94,970
-182
-0.2% -$9.4K 0.25% 102
2023
Q2 		$5.34M Buy
95,152
+2,618
+3% +$149K 0.3% 94
2023
Q1 		$4.19M Buy
92,534
+14,234
+18% +$691K 0.25% 110
2022
Q4 		$3.18M Buy
78,300
+2,215
+3% +$118K 0.22% 115
2022
Q3 		$4.97M Buy
76,085
+27,936
+58% +$2.02M 0.35% 81
2022
Q2 		$2.93M Buy
48,149
+4,912
+11% +$289K 0.22% 106
2022
Q1 		$2.71M Hold
43,237
– – 0.15% 121
2021
Q4 		$3.28M Buy
43,237
+2,838
+7% +$248K 0.17% 122
2021
Q3 		$4.52M Buy
40,399
+452
+1% +$56.8K 0.25% 102
2021
Q2 		$6.47M Sell
39,947
-4,451
-10% -$541K 0.36% 75
2021
Q1 		$5.41M Sell
44,398
-24,951
-36% -$3.77M 0.33% 90
2020
Q4 		$10.6M Buy
69,349
+916
+1% +$108K 0.62% 44
2020
Q3 		$5.72M Buy
+68,433
New +$6.07M 0.39% 66

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International's CRSP Position: Q2 2026 in Review

Capital International held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 56,066 shares worth $3.06M. The position accounts for 0.1% of the portfolio, ranked #133.

Capital International first reported a position in CRSP in Q3 2020 and has held it in 24 quarters since. The position peaked at $10.6M in Q4 2020. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital International held 56,066 shares of CRISPR Therapeutics worth $3.06M as of Q2 2026.
  • Capital International left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.1% of Capital International's portfolio in Q2 2026, its #133 holding.
  • Capital International first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Capital International's CRISPR Therapeutics position peaked at $10.6M in Q4 2020.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital International's 13F filing for Q2 2026, filed 12 Aug 2026.